Medical Use
Diacomit is an anticonvulsant medication used to treat seizures associated with Dravet syndrome in patients aged 6 months and older who are also taking clobazam and weigh at least 7 kg. It is not supported for use as a monotherapy in Dravet syndrome.
Recommended Dosage :
The recommended dose is 50 mg/kg/day, divided into 2 or 3 doses (i.e., 16.67 mg/kg three times daily or 25 mg/kg twice daily), based on the patient’s age and weight. If the exact dosage cannot be achieved with available strengths, round to the nearest possible dose, typically within 50-150 mg of the recommended 50 mg/kg/day. A combination of different Diacomit strengths can be used to achieve this dosage. The maximum recommended total dosage is 3,000 mg per day.
Administration Instructions:
- -Capsules: Swallow whole with a glass of water during a meal. Do not break or open the capsules.
- -Powder for Oral Suspension: Mix in a glass of water (100 mL) and consume immediately during a meal. To ensure no medication is left in the glass, add a small amount of water (25 mL) to the glass and drink the remaining mixture.
Missed Dose :
Take a missed dose as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose and take the next dose as planned. Do not double the doses.
Warning & Precautions
Diacomit, available in 250 mg and 500 mg doses, can cause somnolence. Physicians should assess patients for this side effect and advise them to avoid hazardous activities requiring mental alertness, such as operating heavy machinery or driving, until they understand how the medication affects them.
When taken with other central nervous system (CNS) depressants, including alcohol, Stiripentol may increase the risk of sedation and somnolence.
Stiripentol can also lead to decreased appetite and weight loss. Nausea and vomiting are more common in patients treated with Stiripentol. Due to these side effects, the growth of pediatric patients on this medication should be closely monitored.
Stiripentol capsules can significantly reduce neutrophil and platelet counts. Therefore, hematologic testing is necessary before starting treatment and every six months thereafter.
Like most antiepileptic drugs, Diacomit should be tapered off gradually to minimize the risk of increased seizure frequency and status epilepticus. In cases where rapid withdrawal is required due to severe side effects, appropriate monitoring is essential.
Phenylalanine can be harmful to individuals with phenylketonuria. Diacomit for oral suspension contains phenylalanine, a component of aspartame, with each 250 mg and 500 mg packet containing 1.40 mg and 2.80 mg of phenylalanine, respectively. Before prescribing Diacomit for oral suspension to a patient with phenylketonuria, consider the total daily intake of phenylalanine from all sources. Capsules do not contain phenylalanine.
Antiepileptic drugs (AEDs), including Diacomit in 500 mg or 250 mg doses, may increase the risk of suicidal thoughts or behaviors in individuals taking these medications for any condition. Patients on any AED should be monitored for signs of depression, suicidal thoughts or behaviors, or any unusual changes in mood or behavior.
Patients should inform their healthcare provider if they become pregnant or plan to become pregnant while on Stiripentol therapy. It is recommended that pregnant patients enroll in the NAAED Pregnancy Registry. Additionally, patients should notify their healthcare provider if they are breastfeeding or intend to breastfeed during treatment.
Documentation Availability
Documents required to import DIACOMIT to India?
DIACOMIT (Stiripentol) Capsules can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing DIACOMIT (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for the trade name drug Diacomit®?
Stiripentol is Generic Name for the trade name drug Diacomit®.
What is the Manufacturer Name of Diacomit®?
Diacomit® is manufactured by Biocodex.
Is Diacomit® approved by the FDA?
Yes, Diacomit® is approved by the FDA. Date of first/initial approval: August 20, 2018.
What is the dosage and form of Diacomit® supplied?
Diacomit® is supplied as Capsule and Powder for Oral Suspension in 250 mg/500 mg dosage strength.
Where can I get Diacomit® at the best price in India?
To get the best Diacomit 500 mg/250 mg capsule price in India, contact Rx4u team.
What are the most common side effects with Diacomit®?
The most common side effects with Diacomit® include: decreased appetite, somnolence, agitation, ataxia, weight decreased, nausea, hypotonia, tremor, dysarthria, and insomnia.
How much does Diacomit® cost in India?
Diacomit cost in India is reasonable and can vary. In order to procure this Dravet Syndrome medicine authentically, you can reach out to www.rx4u.in.
What are the storage conditions of Diacomit®?
Store in a dry place at temperature 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F). Store in the original package in order to protect from light.
Is it safe to buy Diacomit® online from India?
Yes, You can buy Diacomit capsule online from India at the best price from https://rx4u.in/
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
